C3N-01030
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 56.87063655
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.290
- TNFA_SIGNALING_VIA_NFKB+0.270
- MYC_TARGETS_V1+0.230
- ALLOGRAFT_REJECTION+0.200
- COMPLEMENT+0.200
- PANCREAS_BETA_CELLS+0.190
- PI3K_AKT_MTOR_SIGNALING+0.190
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.330
- ANDROGEN_RESPONSE-0.250
- BILE_ACID_METABOLISM-0.230
- FATTY_ACID_METABOLISM-0.220
- XENOBIOTIC_METABOLISM-0.210
- KRAS_SIGNALING_DN-0.190
- MYC_TARGETS_V2-0.180
- WNT_BETA_CATENIN_SIGNALING-0.170
- G2M_CHECKPOINT-0.120
- UV_RESPONSE_DN-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A9SX-01A-21R-A39I-07 | — | — | 0.705 |
| 2 | 6815eba1-06e5-46d6-ad4b-e4132b5d1638 | — | — | 0.692 |
| 3 | SRR934794 | — | — | 0.685 |
| 4 | TCGA-49-6761-01A-31R-1949-07 | — | cohortA1 | 0.666 |
| 5 | 8914dcad-b703-4099-a5dd-edb9cedc104c | — | — | 0.665 |
| 6 | TCGA-44-3918-01A-01R-1107-07 | — | cohortA1 | 0.665 |
| 7 | TCGA-44-3396-01A-01R-1206-07 | — | cohortA1 | 0.663 |
| 8 | 2c1c1b9c-180d-44af-b62a-ca9d83ae993f | — | — | 0.663 |
| 9 | a552cdf6.4113.4da4.8e5d.2f3d5555c74e | — | cohortMD2 | 0.663 |
| 10 | SRR934739 | — | — | 0.660 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.410 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |